Video

Dr. Weber on Research Efforts Examining Neoadjuvant Approaches in Melanoma

Jeffrey S. Weber, MD, PhD, discusses research efforts examining neoadjuvant approaches in melanoma.

Jeffrey S. Weber, MD, PhD, deputy director of NYU Langone’s Perlmutter Cancer Center; Laura and Isaac Perlmutter Professor of Oncology in the Department of Medicine at NYU Grossman School of Medicine; and the 2016 OncLiveGiant of Cancer Care® in Melanoma, discusses research efforts examining neoadjuvant approaches in melanoma.

Several exciting studies on neoadjuvant therapy in melanoma have recently been presented, says Weber. One such study was the phase 2 PRADO trial, which was led by Christian Blank, MD, and colleagues from the Netherlands Cancer Institute. In this trial, investigators enrolled patients with measurable, nodal, stage IIIB or IIIC disease and used an injectable device to mark the largest lymph node, Weber adds. Investigators then proceeded to administer neoadjuvant therapy. Following this, they performed a resection, only to look at the marked lymph node, Weber explains.

At the time of the lymphadenectomy, the marked lymph node reflected what happened in all the other lymph nodes perfectly, says Weber. Thus, these data suggest that, investigators can mark a lymph node and if it shows no signs of disease, they should not do anything further.

Additionally, an update from the OpACIN-neo trial, which was a prior study in which everyone had their lymph nodes out; none of them were marked. In this trial, patients were given 2 cycles of ipilimumab (Yervoy) and nivolumab (Opdivo) at flip doses and only a small number of relapses were reported with over 2 years of follow-up, Weber concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity